Delving into the Latest Updates on SPK-843 with Synapse

Overview

Basic Info

Drug Type

Chemical drugs

Synonyms

Amcipatricin, SPA-A-753 (Diaspartate salt)

+ [6]

Target-

Mechanism

Cell membrane modulators

Therapeutic Areas

Infectious DiseasesRespiratory DiseasesOther Diseases

Active Indication-

Inactive Indication

AspergillosisCryptococcosisFungal infection of lung+ [1]

Originator Organization

Società Prodotti Antibiotici SpA

Active Organization-

Inactive Organization

Società Prodotti Antibiotici SpAPRO.PARTS SRL

Kaken Pharmaceutical Co., Ltd.

Drug Highest PhaseDiscontinuedPhase 3

First Approval Date-

Regulation-

Login to view timeline

Structure

Molecular FormulaC67H103N5O19

InChIKeyUJGVOBAKMNJQEV-WHMYMHFRSA-N

CAS Registry143483-67-4

Recruitment of at least 10 adult patients (men and women) among individuals affected and admitted to the hospitals identified for the clinical study. All patients shall be between 18 and 75 years of age, with confirmed diagnosis of cryptococcosis or aspergillosis . During therapy (14 days) and examination (28 days), the patients will be subject to 7 doctor's visits (day 1,3,7,10,14,21, and 28).

Start Date01 May 2010

Sponsor / Collaborator

PRO.PARTS SRL

EUCTR2009-014652-30-IT / Not yet recruitingNot ApplicableIIT

Efficacy, safety and pharmacokinetics of SPK-843 in the treatment of pulmonary mycosis.Phase III Open clinical study - ND

Start Date29 Oct 2009

Sponsor / Collaborator-

100 Clinical Results associated with SPK-843

Login to view more data

100 Translational Medicine associated with SPK-843

Login to view more data

100 Patents (Medical) associated with SPK-843

Login to view more data

15

Literatures (Medical) associated with SPK-843

01 May 2008·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Efficacy of SPK-843, a Novel Polyene Antifungal, in a Murine Model of Systemic Cryptococcosis

Q2 · MEDICINE

Article

Author: Yanagihara, Kazunori ; Seki, Masafumi ; Tashiro, Takayoshi ; Izumikawa, Koichi ; Miyazaki, Yoshitsugu ; Yamamoto, Yoshihiro ; Kohno, Shigeru ; Senda, Hisato ; Kobayashi, Tsutomu ; Kakeya, Hiroshi

ABSTRACT SPK-843, a new polyene antifungal, possessed efficacy in a murine model of systemic infection caused by Cryptococcus neoformans . The administration of 4.0 mg/kg SPK-843 led to better survival prolongation and fungal reduction than those observed with the administration of 0.7 mg/kg amphotericin B and 80 mg/kg fluconazole ( P < 0.001), without histopathological renal changes.

01 May 2008·Antimicrobial Agents and ChemotherapyQ2 · MEDICINE

Efficacy of SPK-843, a Novel Polyene Antifungal, in Comparison with Amphotericin B, Liposomal Amphotericin B, and Micafungin against Murine Pulmonary Aspergillosis

Q2 · MEDICINE

Article

Author: Seki, Masafumi ; Tashiro, Takayoshi ; Yamamoto, Yoshihiro ; Izumikawa, Koichi ; Yanagihara, Kazunori ; Miyazaki, Yoshitsugu ; Kohno, Shigeru ; Senda, Hisato ; Kobayashi, Tsutomu ; Kakeya, Hiroshi

ABSTRACTSPK-843, a new polyene antifungal, exhibited dose-dependent efficacy on murine pulmonary aspergillosis models. SPK-843 doses of higher than 1.0 mg/kg of body weight exhibited no renal toxicities and a tendency toward better survival prolongation than the estimated maximum tolerated doses of amphotericin B (Fungizone) (1.0 mg/kg) and liposomal amphotericin B (AmBisome) (8.0 mg/kg).

01 Aug 2005·Current opinion in investigational drugs (London, England : 2000)

SPK-843 (Aparts/Kaken).

Review

Author: Kasanah, Noer ; Hamann, Mark T

SPK-843 is a water-soluble antibiotic under co-development by Aparts and Kaken for the potential treatment of systemic fungal infections. By November 2004, SPK-843 was in phase II trials for systemic mycosis.

100 Deals associated with SPK-843

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB12333

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Fungal infection of lung	Phase 3	IT	PRO.PARTS SRL	01 May 2010
Aspergillosis	Phase 3	-	Società Prodotti Antibiotici SpA	-
Aspergillosis	Phase 3	-	Kaken Pharmaceutical Co., Ltd.	-
Cryptococcosis	Phase 3	-	Kaken Pharmaceutical Co., Ltd.	-
Cryptococcosis	Phase 3	-	Società Prodotti Antibiotici SpA	-
Cryptococcosis	Phase 3	-	Kaken Pharmaceutical Co., Ltd.	-
Cryptococcosis	Phase 3	-	Società Prodotti Antibiotici SpA	-
Mycoses	Phase 3	JP	Kaken Pharmaceutical Co., Ltd.	-
Aspergillosis	Preclinical	-	Kaken Pharmaceutical Co., Ltd.	-
Aspergillosis	Discovery	-	Società Prodotti Antibiotici SpA	-